Funder
Commonwealth Department of Health
Gastroenterological Society of Australia
The University of Queensland
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Reference25 articles.
1. Deloitte Access Economics. The economic cost and health burden of liver diseases in Australia. Sydney: Gastroenterological Society of Australia/Australian Liver Association; 2013.
2. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21:34–59.
3. Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, Selvey C et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales. Australia. J Hepatol 2019;71:281–288.
4. Lee A, Hanson J, Fox P, Spice G, Russell D, Boyd P. A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia. J Virus Erad 2018;4:160–164.
5. Gupta S, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R et al. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. J Viral Hepat 2018;25:771–778.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献